Medications for Angioedemas Hereditary
10 results
Berinert (human c1-esterase inhibitor)
(HUMAN C1-ESTERASE INHIBITOR)CSL Behring GmbH
Usage: BERINERT is indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in both adult and pediatric patients. Its safety and efficacy for prophylactic therapy have not been established.
Cinryze (human c1-esterase inhibitor)
(HUMAN C1-ESTERASE INHIBITOR)Takeda Pharmaceuticals America, Inc.
Usage: CINRYZE is indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (ages 6 and older) with Hereditary Angioedema (HAE).
Firazyr (icatibant acetate)
(icatibant acetate)Takeda Pharmaceuticals America, Inc.
Usage: FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years and older.
Haegarda (human c1-esterase inhibitor)
(HUMAN C1-ESTERASE INHIBITOR)CSL Behring GmbH
Usage: HAEGARDA is a plasma-derived C1 Esterase Inhibitor indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients aged 6 years and older.
Icatibant (icatibant)
(Icatibant)Alembic Pharmaceuticals Inc.
Usage: Icatibant injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.
Kalbitor (ecallantide)
(Ecallantide)Takeda Pharmaceuticals America, Inc.
Usage: KALBITOR® (ecallantide) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
Orladeyo (berotralstat hydrochloride)
(Berotralstat hydrochloride)BioCryst Pharmaceuticals Inc.
Usage: ORLADEYO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older. It is not approved for treating acute HAE attacks, and doses exceeding 150 mg daily are not recommended due to potential QT prolongation risks.
Ruconest (c1 esterase inhibitor recombinant)
(c1 esterase inhibitor recombinant)Tjoapack Netherlands BV
Usage: RUCONEST is indicated for treating acute attacks in adults and adolescents with hereditary angioedema (HAE). However, its effectiveness in patients experiencing laryngeal attacks has not been established.
Sajazir (icatibant)
(ICATIBANT)Cycle Pharmaceuticals Ltd-Uk
Usage: SAJAZIR (icatibant) injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 and older.
Takhzyro (lanadelumab-flyo)
(lanadelumab-flyo)Takeda Pharmaceuticals America, Inc.
Usage: TAKHZYRO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 2 years and older.